Riset dan Pengabdian Masyarakat
Do Research Sosial Service and Innovation
Publikasi Scopus 926 artikel (Per 14 Maret 2022)
Publikasi Scopus 926 artikel (Per 14 Maret 2022)
Beta-blocker attenuates cardiotoxicity related anthracycline usage
2021
Journal of the Medical Association of Thailand
104
8
1389
1392
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85113310208&doi=10.35755%2fjmedassocthai.2021.08.9268&partnerID=40&md5=ee18aa74520b3a2ce8f163a390c84499
Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Indonesia
To summarize the recent trials and studies of the role of beta-blocker on the treatment for cancer patients treated with anthracycline to decrease morbidity and mortality rate. Good management of cancer will result in large numbers of cancer survivors. On the other hand, cancer therapy also has side effects, one of which is cardiotoxicity. Cardiotoxicity could reduce therapy effectiveness, hence, increase disease progression and mortality rate. Anthracyclines is one of the chemotherapy agents with cardiotoxicity as a side effect. Beta-blocker has the ability to reduce cardiotoxicity due to anthracyclines usage. © JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND.
alprenolol; amino terminal pro brain natriuretic peptide; anthracycline; beta adrenergic receptor; beta adrenergic receptor blocking agent; beta arrestin; carvedilol; deubiquitinase; DNA topoisomerase (ATP hydrolysing); doxorubicin; epidermal growth factor receptor; epirubicin; G protein coupled receptor; guanosine triphosphatase; histone deacetylase; hydroxyl radical; nebivolol; peroxisome proliferator; protein p53; reactive nitrogen species; reactive oxygen metabolite; reduced nicotinamide adenine dinucleotide phosphate oxidase; sodium chloride; apoptosis; autophagy (cellular); blood pressure; breast cancer; cancer therapy; cancer tissue; cardiac muscle cell; cardiac stem cell; cardiomyopathy; cardiotoxicity; cardiovascular disease; cardiovascular risk factor; cell death; cell membrane;
Medical Association of Thailand
01252208
Review
#N/A
#N/A
#N/A